Physician

Neurology

Dr. Bibiana Bielekova, MD

Bibiana Bielekova practices Neurology. Dr. Bibiana Bielekova is also a published doctor. She has 44 publication published. The most recent publication is: Novel composite MRI scale correlates highly with disability in multiple sclerosis patients.

Publications

Novel composite MRI scale correlates highly with disability in Multiple sclerosis patients.
CSF markers reveal intrathecal inflammation in progressive Multiple sclerosis.
Comprehensive Immunophenotyping of Cerebrospinal Fluid Cells in Patients with Neuroimmunological Diseases.
Daclizumab-induced adverse events in Multiple organ systems in Multiple sclerosis.
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy.
CNS vasculitis in a patient with MS on daclizumab monotherapy.
Daclizumab therapy for Multiple sclerosis.
Cerebrospinal Fluid IL-12p40, CXCL13 and IL-8 as a Combinatorial Biomarker of Active Intrathecal Inflammation.
Inhibition of LTi Cell Development by CD25 Blockade Is Associated with Decreased Intrathecal Inflammation in Multiple Sclerosis.
How implementation of systems biology into clinical trials accelerates understanding of diseases.
Antigen-specific immunomodulation via altered peptide ligands.
Complex immunomodulatory effects of interferon-beta in Multiple sclerosis include the upregulation of T helper 1-associated marker genes.
Molecular mimicry and antigen-specific T cell responses in Multiple sclerosis and chronic CNS Lyme disease.
Lessons from studies of antigen-specific T cell responses in Multiple Sclerosis.
Mechanisms of immunomodulation by glatiramer acetate.
VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in Multiple sclerosis.
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in Multiple sclerosis: results of a phase II clinical trial with an altered peptide ...
Human autoreactive CD4+ T cells from naive CD45RA+ and memory CD45RO+ subsets differ with respect to epitope specificity and functional antigen avidity.
Preferential expansion of autoreactive T lymphocytes from the memory T-cell pool by IL-7.
Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases.
Myelin-associated oligodendrocytic basic protein: identification of an encephalitogenic epitope and association with Multiple sclerosis.
Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease.
The effect of vesnarinone on TNF alpha production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of Multiple sclerosis.
Intrathecal effects of daclizumab treatment of Multiple sclerosis.
MRI as a marker for disease heterogeneity in Multiple sclerosis.
Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b.
Comment on "Interleukin-2/Interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation".
Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders.
Development of biomarkers in Multiple sclerosis.
Humanized anti-CD25 (daclizumab) inhibits disease activity in Multiple sclerosis patients failing to respond to interferon beta.
Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in Multiple sclerosis.
Gene expression profile in Multiple sclerosis patients and healthy controls: identifying pathways relevant to disease.
Evolution of the blood-brain barrier in newly forming Multiple sclerosis lesions.
Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of Multiple sclerosis.
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy.
National Institutes of Health Center for Human Immunology Conference, September 2009.
An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.
Monoclonal antibodies in MS: mechanisms of action.
Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in Multiple sclerosis.
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in Multiple sclerosis.
Emerging therapies for Multiple sclerosis.
Biomarkers in Multiple sclerosis.
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in Multiple sclerosis.

Schools

University Komenskeho Lekarska Fak Martin Czechoslovakia

Conditions Treated

Multiple Sclerosis (MS)

Doctors Specialties

Neurology

Accepted Insurances

Education

Boston University Medical Center
SUNY Health Science Center at Brooklyn
Comenius University

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Tasha R. Powell, MD
	Dr. Carmina A. Domingo, DO
	Dr. Philip Eye, MD
	Dr. Carl H. Gunderson, MD
	Dr. Zurab Nadareishvili, MD This Doctor is OpenDoctor Recommended.
	Dr. Gloria H. Von Geldern, MD
	Dr. Renwu Chen, MD
	Dr. Olavo M. Vasconcelos Jr., MD This Doctor is OpenDoctor Recommended.
	Dr. Joohee Sul, MD
	Dr. Joseph A. Miller Jr., MD This Doctor is OpenDoctor Recommended.